COMPARISON OF 4F-PCC AND ANDEXANET ALFA FOR REVERSAL OF APIXABAN- AND RIVAROXABAN-ASSOCIATED ICH

被引：0
|
作者：
Lipski, Michelle [1 ]
Pasciolla, Stacy [2 ]
Wojcik, Kevin [3 ]
Jankowitz, Brian [4 ]
Igneri, Lauren [5 ]
机构：
[1] UPMC Hamot, Erie, PA USA
[2] Philadelphia Coll Pharm, Philadelphia, PA USA
[3] Philadelphia Coll Osteopath Med, Philadelphia, PA USA
[4] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[5] Cooper Univ Hosp, Camden, NJ USA
来源：
CRITICAL CARE MEDICINE | 2022年 / 50卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
769
引用
收藏
页码：378 / 378
页数：1
相关论文
共 50 条
  • [1] Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages
    Pham, Haithuy
    Medford, Whitney Gibson
    Horst, Spencer
    Levesque, Melissa
    Ragoonanan, David
    Price, Christine
    Colbassani, Harold
    Piper, Keaton
    Chastain, Keith
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 55 : 38 - 44
  • [2] Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages
    Barra, Megan E.
    Das, Alvin S.
    Hayes, Bryan D.
    Rosenthal, Eric S.
    Rosovsky, Rachel P.
    Fuh, Lanting
    Patel, Aman B.
    Goldstein, Joshua N.
    Roberts, Russel J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) : 1637 - 1647
  • [3] Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
    Costa, Olivia S.
    Connolly, Stuart J.
    Sharma, Mukul
    Beyer-Westendorf, Jan
    Christoph, Mary J.
    Lovelace, Belinda
    Coleman, Craig I.
    CRITICAL CARE, 2022, 26 (01)
  • [4] Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
    Olivia S. Costa
    Stuart J. Connolly
    Mukul Sharma
    Jan Beyer-Westendorf
    Mary J. Christoph
    Belinda Lovelace
    Craig I. Coleman
    Critical Care, 26
  • [5] FEIBA AND ANDEXANET ALFA FOR THE REVERSAL OF APIXABAN AND RIVAROXABAN IN UNCONTROLLED HEMORRHAGE
    Ice, Calvin
    Gurka, Matthew
    Parker, Jessica
    Hunt, Aleah
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 449 - 449
  • [6] Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
    Bradshaw, Paige Garber
    Keegan, Shaun Patrick
    Droege, Molly Elizabeth
    Dykes, Nicole Jade Harger
    Ernst, Neil Edward
    Foertsch, Madeline Jane
    Makley, Amy Teres
    Mueller, Eric William
    Philpott, Carolyn Dosen
    Srinivasan, Vasisht
    Winter, Jessica Brooke
    Goodman, Michael D.
    Droege, Christopher Allen
    PHARMACOTHERAPY, 2022, 42 (10): : 780 - 791
  • [7] Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate
    Sheikh-Taha, Marwan
    INTERNAL AND EMERGENCY MEDICINE, 2019, 14 (02) : 265 - 269
  • [8] Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate
    Marwan Sheikh-Taha
    Internal and Emergency Medicine, 2019, 14 : 265 - 269
  • [9] Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage
    Michelle Lipski
    Stacy Pasciolla
    Kevin Wojcik
    Brian Jankowitz
    Lauren A. Igneri
    Journal of Thrombosis and Thrombolysis, 2023, 55 : 519 - 526
  • [10] PHASE 3 OF ANDEXANET ALFA FOR REVERSAL OF APIXABAN AND RIVAROXABAN ANTICOAGULATION IN OLDER SUBJECTS
    Crowther, Mark
    Gold, Alex
    Lu, Genmin
    Leeds, Janet
    Wiens, Brian
    Conley, Pamela
    Connolly, Stuart
    Curnutte, John
    CRITICAL CARE MEDICINE, 2015, 43 (12)
12345